Overview

Effects of Arzoxifene on Bone Mass and the Uterus

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine: - The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. - The effects of arzoxifene on the uterus (womb) in postmenopausal women. - The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. - The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. - The safety of arzoxifene and any side effects that might be associated with its use.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company